Open AccessSusceptibility to antibiotic combinations of Klebsiella pneumoniae and Acinetobacter baumannii strains isolated from COVID-19 patients
Author(s) -
D. V. Tapalski,
Е. В. Карпова
Publication year - 2021
Publication title -
problemy zdorovʹâ i èkologii
Language(s) - English
Resource type - Journals
eISSN - 2708-6011
pISSN - 2220-0967
DOI - 10.51523/2708-6011.2021-18-4-4
Subject(s) - colistin , acinetobacter baumannii , broth microdilution , meropenem , microbiology and biotechnology , klebsiella pneumoniae , antibiotics , minimum inhibitory concentration , biology , medicine , antibiotic resistance , pseudomonas aeruginosa , bacteria , escherichia coli , biochemistry , genetics , gene
Objective. To assess the susceptibility of K.pneumoniae and A.baumanii strains isolated from hospitalized COVID-19 patients to antibiotics and their combinations. Materials and methods. The minimum inhibitory concentrations (MICs) of meropenem and colistin were determined for 47 A.baumannii and 51K.pneumoniae strains isolated from the hospitalized COVID-19 patients by the broth microdilution method. The susceptibility to 11 antibiotic combinations was assessed using the method of multiple combination bactericidal testing. Results. Colistin resistance was detected in 31.9 % of A.baumannii strains (MIC 50 — 0.5 mg/l, MIC 90 — 16 mg/l) and in 80.4 % of K.pneumoniae strains (MIC 50 — 16 mg/l, MIC 90 — 256 mg/l). It has been shown that double antibiotic combinations with the inclusion of colistin exhibit bactericidal or bacteriostatic activity against 76.6–87.2 % of A.baumannii strains. Combinations with the addition of meropenem, colistin and macrolides exhibited bactericidal activity against 78.4–80.4 % of K.pneumoniae strains. Combinations of two carbapenems were not active, the combination of meropenem-colistin had a bactericidal effect only in 13.7 % of K.pneumoniae strains. Conclusion. Widespread colistin resistance was found in carbapenem-resistant K.pneumoniae and A.baumannii strains isolated from the hospitalized COVID-19 patients. The combinations of antibiotics that have a synergistic antibacterial effect in their pharmacokinetic/pharmacodynamic concentrations have been determined.